Search

Pharmaceuticals Production GEA Pharma Systems Supplies Pharmaceuticals Production in Wales

| Editor: Dominik Stephan

Penn Pharma, a leading contract manufacturer in the UK, has selected GEA to provide fully integrated production line for contained pharmaceutical development and production in South Wales.

Related Companies

Leading contract manufacturer Penn Pharma in UK has chosen GEA Pharma Systems as key supplier to provide a fully integrated production line for contained development and production
Leading contract manufacturer Penn Pharma in UK has chosen GEA Pharma Systems as key supplier to provide a fully integrated production line for contained development and production
(Picture: PROCESS India)

Tredegar/United Kingdom – Penn Pharma believes that the new equipment will significantly increase the pharmaceutical contract manufacturer’s production capacity and allow it to provide a single source for high containment development and manufacture of highly potent drugs for its international customers.

Mark Dean Netscher, the company’s COO, explained that last year they decided to expand manufacturing capacity to provide pharmaceutical companies with a unique partner. “Large pharmaceutical companies often have their own R&D facilities but choose to outsource larger volume production,” he explained. “There are few companies around the world that are capable of providing the quality and range of capacities required, while ensuring the high levels of containment without resorting to cumbersome isolation suits. Today, those old ways are just not acceptable.”

Pharmaceuticals Production With Sealed Components

The GEA equipment for the production facility at Tredegar includes highly contained materials handling from Buck Systems based on Buck MC valves and Hicoflex; a PharmaConnect line for product formulation and for production high shear granulation and blending; FlexStream fluid bed technology; and the Modul P tablet press with the unique Exchangeable Compression Module that keeps all the product contact parts within a sealed unit.

The company believes that its new facility will be leading edge and a vitally important resource for the world’s leading pharmaceutical companies. “Not only will we have increased capacity, we will also be able to provide scale-up capability from small-scale development batches, through clinical trials requirements, right up to commercial production in one facility using the same equipment as many of our customers and using the latest engineering controls to maintain a clean environment that does not expose people to harm,” explained Jerome.

(ID:34127770)